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Edited by Masayuki MiyasakaAbstract We investigated whether lysophosphatidylethanol-
amine (LPE) modulates cellular signaling in diﬀerent cell types.
SK-OV3 ovarian cancer cells and OVCAR-3 ovarian cancer
cells were responsive to LPE. LPE-stimulated intracellular
calcium concentration ([Ca2+]i) increase was inhibited by U-
73122, suggesting that LPE stimulates calcium signaling via
phospholipase C activation. Moreover, pertussis toxin (PTX)
almost completely inhibited [Ca2+]i increase by LPE, indicating
the involvement of PTX-sensitive G-proteins. Furthermore, we
found that LPE stimulated chemotactic migration and cellular
invasion in SK-OV3 ovarian cancer cells. We examined the role
of lysophosphatidic acid receptors on LPE-stimulated cellular
responses using HepG2 cells transfected with diﬀerent LPA
receptors, and found that LPE failed to stimulate nuclear factor
kappa B-driven luciferase. We suggest that LPE stimulates a
membrane bound receptor, diﬀerent from well known LPA
receptors, resulting in chemotactic migration and cellular inva-
sion in SK-OV3 ovarian cancer cells.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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It is well known that lysophospholipids such as lysophos-
phatidic acid (LPA) act as lipid ligands which stimulate diverse
cellular responses [1,2]. LPA has been reported to induce cellu-
lar proliferation in primary ovarian carcinoma cells, prostate
cancer cell lines, amnionic cells, chondrocytes, and so on
[3–5]. LPA also induces cellular migration and invasion inAbbreviations: LPA, lysophosphatidic acid; LPS, lysophosphatidyl-
serine; LPG, lysophosphatidylglycerol; GPCR, G-protein coupled
receptor; LPE, lysophosphatidylethanolamine; fura-2/AM, fura-2
pentaacetoxymethylester; PTX, pertussis toxin; ERK, extracellular
signal regulated protein kinase; [Ca2+]i, intracellular calcium concen-
tration; PLC, phospholipase C; NF-jB, nuclear factor kappa B
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[6,7]. In terms of cell surface receptors for LPA, certain type
of G-protein coupled receptor (GPCR) such as LPA1, LPA2,
and LPA3 have been reported [8,9]. In addition to LPA, other
lysophospholipids including lysophosphatidylserine (LPS) and
lysophosphatidylglycerol (LPG) also reported to act as bioac-
tive lipid ligands [10–12]. LPS stimulated leukemic cells and
mouse ﬁbroblasts, resulting in cellular migration [10,11].
LPG stimulated OVCAR-3 human ovarian cancer cells, result-
ing in intracellular calcium increase and mitogen-activated
protein kinase activation [12]. The facts that LPA has been re-
ported to regulate a plethora of cellular activity in many cell
types, and LPS and LPG act as novel bioactive lysophospho-
lipids led us to check role of other lysophospholipids such as
lysophosphatidylethanolamine (LPE).
LPE can be generated from the hydrolysis of phosphatidyl-
ethanolamine, a component of cell membrane, by phospho-
lipase A2. Recently LPE in Grifola frondosa was reported to
stimulate mitogen-activated protein kinase, resulting in anti-
apoptotic activity in PC12 cells [13]. Very recently LPE has
been known to induce reversible skeletal neuromuscular paral-
ysis, indicating LPE as a novel agent to study neuroexocytosis
[14]. However, roles of LPE in the modulation of biological
responses have been poorly studied. LPE’s role in various cel-
lular activities and its mechanism of action should be investi-
gated.2. Materials and methods
2.1. Reagents
1-Oleoyl-2-hydroxy-sn-glycero-3-phospho-ethanolamine (LPE) and
Na+ lysophosphatate (LPA) were purchased from Avanti Polar Lipids
Inc. (Alabaster, Alabama). Stock solutions of the two lipids (20 mM
each) were prepared by dissolving them in distilled water and subse-
quent sonication. Any carrier protein such as bovine serum albuminwas
not used for the preparation of LPE and LPA. Fura-2 pentaacetoxy-
methylester (fura-2/AM) was purchased from Molecular Probes
(Eugene, OR). 1-[6-((17b-3-Methoxyestra-1,3,5(10)-trien-17-yl)amino)
hexyl]-1H-pyrrole-2,5-dione (U-73122), 1-[6-((17b-3-methoxyestra-1,3,
5(10)-trien-17-yl)amino)hexyl]-2,5-pyrrolidinedione (U-73343), and
pertussis toxin (PTX) were purchased from Calbiochem (San Diego,
CA).2.2. Cell culture
SK-OV3 human ovarian cancer cells and OVCAR-3 human ovarian
cancer cells were obtained from the American Type Culture Collectionblished by Elsevier B.V. All rights reserved.
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incubator, and maintained in RPMI 1640 culture medium containing
10% heat-inactivated fetal bovine serum (FBS). U937 (human histio-
cytic lymphoma cells), Hela (human cervical cancer cells), HCT116
(human colorectal carcinoma cells), MCF7 (human breast cancer
cells), and A431 (human epidermoid carcinoma cells) were maintained
as recommended.
2.3. Ca2+ measurement
Intracellular calcium concentration ([Ca2+]i) was determined by
Grynkiewicz’s method using fura-2/AM [15]. Brieﬂy, prepared cells
were incubated with 3 lM fura-2/AM at 37 C for 50 min in serum free
RPMI 1640 medium with continuous stirring. 2 · 106 cells were ali-
quoted for each assay into Locke’s solution (154 mM NaCl, 5.6 mM
KCl, 1.2 mM MgCl2, 5 mM HEPES, pH 7.3, 10 mM glucose,
2.2 mM CaCl2, and 0.2 mM EGTA). Fluorescence was measured at
500 nm at excitation wavelengths of 340 nm and 380 nm.
2.4. Chemotaxis assay
Chemotaxis assays were performed using multiwell chambers
(Neuroprobe Inc., Gaithersburg, MD) as described previously [11].
Brieﬂy, polycarbonate ﬁlters (8 lm pore size) were precoated with
20 lg/ml of ﬁbronectin in 0.25% acetic acid solution. A dry coated
ﬁlter was placed on a 96-well chamber containing diﬀerent concentra-
tions of LPE. OVCAR3 cells were suspended in RPMI 1640 medium at
a concentration of 1 · 106 cells/ml, and 25 ll of the cell suspension
were placed onto the upper well of the chamber. After incubation
for 4 h at 37 C, non-migrating cells were removed by scraping, and
cells that migrated across the ﬁlter were dehydrated, ﬁxed, and stained
with hematoxylin (Sigma, St. Louis, MO). The stained cells in ﬁve
randomly chosen high power ﬁelds (HPF, 400·) were then counted
for each well.
2.5. Invasion assay
Invasion assays were performed using modiﬁed Boyden chambers
with polycarbonate nucleopore membrane (Corning, Corning, NY),
as described before [16]. Precoated ﬁlters (6.5 mm in diameter, 8 lm
pore size, Matrigel 100 lg/cm2) were rehydrated with 250 ll of med-
ium, and 5 · 104 cells in 200 ll medium were cultured in the absence
or presence of several concentrations of LPE, or vehicle (DDW) were
placed in the upper well. After incubation for 24 h at 37C, non-migra-
tory cells on the upper surface of the ﬁlter were wiped with a cotton
swab, and migrated cells on the lower surface of the ﬁlter were
ﬁxed and stained with 0.125% Coomassie Blue in a methanol:acetic
acid:water mixture (45:10:45 v/v/v). Random ﬁelds were counted under
a light microscope.
2.6. RT-PCR analysis
mRNA was isolated by using a QIAshredder and an RNeasy kit
(Qiagen, Hilden, Germany). mRNA, M-MLV reverse transcriptase,
and pd(N)6 primers (Invitrogen Corp., Carlsbad, CA) were used to
obtain cDNA. The sequences of the primers used were as follows;
LPA1 receptor: forward, 5
0-TCT TCT GGG CCA TTT TCA AC-3 0;
reverse, 5 0-TGC CTR AAG GTG GCG CTC AT-3 0. LPA2 receptor:
forward, 5 0-CCT ACC TCT TCC TCA TGT TC-3 0; reverse, 5 0-TAA
AGG GTG GAG TCC ATC AG-3 0. LPA3receptor: forward, 5 0-
GGA ATT GCC TCT GCA ACA TCT-3 0; reverse, 5 0-GAG TAG
ATG ATG GGG TTC A-3 0. LPA4 receptor: forward, 5 0-GGC TTT
GTG GTC AAA GGT GT-3 0; reverse, 5 0-TGC GCT CCC AAG
CTA TTA CT-30. LPA5 receptor: forward, 5 0-CAA AGT GGG
ATT GGG AGC TA-3 0; reverse, 5 0-GCT GAT GAA GCT GTG
ACC AA-3 0. GAPDH: forward, 5 0-GAT GAC ATC AAG AAG
GTG GTG AA-3 0, reverse, 5 0-GTC TTA CTC CTT GGA GGC
CAT GT-3 0. Ampliﬁcation was performed over 35 cycles {94 C/
1 min (denaturation), 60 C/1 min (annealing), and 72C/1 min (exten-
sion)}. PCR products were electrophoresed on a 2% agarose gel and
visualized by ethidium bromide staining.2.7. Luciferase assay
Human LPA1, LPA2, and LPA3 cDNAs were a gift from P.G. Suh
(POSTECH, Korea). Human LPA4, and LPA5 cDNAs were a gift
from K.R. Lynch (University of Virginia, Virginia). Nuclear factor
kappa B (NF-jB) reporter construct was purchased from Clonetech(Palo Alto, CA). HepG2 cells were plated in six-well plates at a density
of 5 · 105 cells/well and grown overnight. Cells were transfected with
2 lg of each plasmid construct for 6 h by the Lipofectamine method.
After transfection, HepG2 cells were cultured in 10% FBS containing
DMEM medium with LPA (10 lM) or LPE (2 lM) for 20 h. Cells
were lysed with lysis buﬀer (20 mM Tris–HCl, pH 7.8, 1% Triton
X-100, 150 mM NaCl, 2 mM DTT). The cell lysate 25 ll was mixed
with luciferase activity assay reagent 25 ll and luminescence produced
for 15 s was measured using luminoskan (labsystems).
2.8. Statistics
The results are expressed as means ± S.E. of the number of determi-
nations indicated. Statistical signiﬁcance of diﬀerences was determined
by Student t-test. Signiﬁcance was accepted when P < 0.05.3. Results
3.1. LPE stimulates calcium mobilization in SK-OV3 ovarian
cancer cells
We examined the eﬀects of LPE on intracellular calcium
release in multiple cell types. At ﬁrst we found that LPE stim-
ulated [Ca2+]i rise in two human ovarian cancer cells, SK-OV3
and OVCAR-3 (Fig. 1A). U937 (human histiocytic lymphoma
cells), Hela (human cervical cancer cells), HCT116 (human
colorectal carcinoma cells), MCF7 (human breast cancer cells),
and A431 (human epidermoid carcinoma cells) showed no
response to LPE in terms of [Ca2+]i rise (Fig. 1A). The results
suggest that the eﬀect of LPE is speciﬁc for human ovarian
cancer cells.
We, then, examined concentration-dependency of LPE
upon [Ca2+]i increase in SK-OV3 ovarian cancer cells. As
shown in Fig. 1B, increase of [Ca2+]i was apparent at 1 lM
of LPE and maximal activity was observed at 5–10 lM
(Fig. 1B).3.2. LPE-induced [Ca2+]i increase is mediated via G-proteins
and phospholipase C
Since phospholipase C (PLC) has been known to play a key
role in [Ca2+]i increase [17], we examined the role of PLC on
LPE-stimulated [Ca2+]i increase using a speciﬁc PLC inhibitor,
U-73122 and its inactive analogue U-73343. Fig. 2A shows
that U-73122, but not U-73343, completely inhibited LPE-
induced [Ca2+]i increase. This result indicates that LPE stimu-
lates [Ca2+]i increase via PLC activation in SK-OV3 ovarian
cancer cells. We also examined the eﬀect of PTX, a speciﬁc
inhibitor of Gi/o type G proteins, to check involvement of
PTX-sensitive G-proteins on LPE-induced [Ca2+]i increase.
When SK-OV3 ovarian cancer cells were preincubated with
100 ng/ml of PTX prior to being stimulated with 2 lM LPE,
LPE-induced [Ca2+]i increase was almost completely inhibited
(Fig. 2B). These results indicate that LPE stimulates [Ca2+]i
increase via PTX-sensitive G proteins.3.3. LPE stimulates chemotactic migration of SK-OV3 ovarian
cancer cells via PTX-sensitive G-proteins
We examined the eﬀect of LPE on chemotactic migration in
several cancer cell lines. LPE only stimulated chemotactic
migration in SK-OV3 cells but not in the other cells
(OVCAR-3, U937, Hela, HCT116, MCF7, and A431) (data
not shown). As shown in Fig. 3A, LPE signiﬁcantly stimulated
chemotactic migration of SK-OV3 ovarian cancer cells in a
concentration-dependent manner, showing bell-shape with
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Fig. 2. LPE-induced Ca2+ signaling is mediated through PLC and
PTX-sensitive G-protein in SK-OV3 cells. SK-OV3 cells were pre-
treated with 5 lM of U-73122 or 5 lM of U-73343 for 5 min prior to
10 lM of LPE, and [Ca2+]i was determined (A). SK-OV3 cells were
preincubated in the absence or presence of 100 ng/ml of PTX for 24 h.
SK-OV3 cells were then loaded with fura-2/AM and [Ca2+]i was
determined ﬂuorometrically after stimulation with 10 lM of LPE (B).
Relative intracellular Ca2+ concentrations are expressed as ﬂuores-
cence ratios (340:380 nm). Data are representative of four independent
experiments (A and B).
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Fig. 1. LPE stimulates [Ca2+]i increase in human ovarian cancer cells.
SK-OV3, OVCAR-3, U937, Hela, HCT116, MCF-7 and A431 cells
were loaded with fura-2 and stimulated with 10 lM of LPE (A). SK-
OV3 human ovarian cancer cells were stimulated with several
concentrations of LPE (B). The peak level of [Ca2+]i was recorded.
Results are presented as mean ± S.E. of three independent experi-
ments, which performed in duplicate (A and B). *P < 0.05 from vehicle
treated.
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LPE-induced chemotaxis and chemokinesis, we performed
migration assays in the absence or presence of LPE in the
upper wells of Boyden chambers as described previously [11].
The addition of LPE (20 lM) to the upper chamber reduced
the LPE-induced migrations of SK-OV3 cells to the lower well,
thus demonstrating that LPE induces SK-OV3 ovarian cancer
cell chemotaxis (Fig. 3A). Since LPE-induced calcium signal-
ing was inhibited by PTX in SK-OV3 cells, we examined the
eﬀect of PTX on LPE-induced SK-OV3 cell chemotaxis. When
SK-OV3 cells were preincubated with 100 ng/ml of PTX prior
to chemotaxis assays, the numbers of cells migrating toward
LPE was reduced about above 95% (Fig. 3B), which strongly
suggested the involvement of PTX-sensitive G proteins on
the chemotactic migration.
3.4. LPE stimulates SK-OV3 in vitro invasion
Since LPA has been reported to induce cellular invasion in
ovarian cancer cells, we also investigated the eﬀect of LPE
on SK-OV3 in vitro invasion. Stimulation of SK-OV3 cells
with several concentrations of LPE elicited cellular invasion
in a concentration-dependent manner (Fig. 4). Maximal activ-
ity was shown at 1 lM of LPE (Fig. 4). The LPE-induced
invasion activity was comparable with LPA-induced one
(Fig. 4).3.5. LPE-induced [Ca2+]i increase is independent of LPA
receptors
In terms of cell surface receptors for LPE, we suspected a
possibility of that LPE utilizes GPCRs for LPA to elicit
Ca2+ response and tested it by using desensitization experi-
ments. As shown in Fig. 5A, stimulation of SK-OV3 ovarian
cancer cells with LPE desensitized cells, resulting in no
response to the second LPE stimulation, meaning homologous
desensitization. The homologous desensitization was also
observed with LPA. However, LPE-desensitized SK-OV3
ovarian cancer cells responded to LPA (Fig. 5A). Moreover,
LPA-desensitized SK-OV3 ovarian cancer cells were also
responding to LPE (Fig. 5A). Therefore, these results exclude
the above possibility and suggest that LPE may have a certain
receptor which is diﬀerent to the known LPA receptors.
We also examined the eﬀect of two kinds of LPA receptor
antagonists (VPC32183 and Ki16425) [18,19] on LPE-induced
calcium signaling. Preincubation of SK-OV3 cells with 10 lM
VPC32183 (an LPA1 and LPA3-selective antagonist) caused
complete inhibition of LPA-induced calcium signaling
(Fig. 5B). However, LPE-stimulated calcium signaling was
not aﬀected by VPC32183 (Fig. 5B). Another LPA receptor
antagonist, Ki16425 (an LPA1 and LPA3-selective antagonist)
also completely inhibited calcium signaling induced by LPA
but not by LPE (Fig. 5C). The results indicate that LPE stim-
ulates calcium signaling in an LPA receptors-independent
manner.
We then investigated which type of LPA receptors are
expressed in SK-OV3 cells by RT-PCR analysis. As shown in
Fig. 6A, SK-OV3 expressed three of LPA receptors; LPA2,
LPA3, and LPA4 but not LPA1 and LPA5. Other cancer cell
lines also expressed certain type of LPA receptors (Fig. 6A).
To further support our notion that LPE has distinct receptors
M
ig
ra
te
d 
Ce
lls
LPE (μM) LPA (μM)
0
100
200
300
 -PTX
 +PTX
M
ig
ra
te
d 
Ce
lls
LPE (μM)
0                    1                  10
B
A
*
*
# #
0 0.01 0.1 1 10 20 250
200
400
600
800  -LPE
 +LPE
*
*
*
*
*
*
#
# # #
#
Fig. 3. LPE induces SK-OV3 cell chemotaxis. Assays were performed
using a modiﬁed Boyden chamber assay as described in Section 2.
Polycarbonate membrane of 96-well chemotaxis chamber was pre-
coated with ﬁbronectin (20 lg/ml) in 0.25% acetic acid solution
overnight at room temperature. Cultured SK-OV3 cells (1 · 106 cells/
ml in serum free RPMI) were added to the upper well of a 96-well
chemotaxis chamber and migration across a polycarbonate membrane
of 8 lm pore size was assessed in the absence or presence LPE or LPA
for 4 h at 37 C. Various concentrations of LPE were used for the
chemotaxis assay in the absence or presence of LPE (20 lM) in the
upper well (A). () LPE indicates the absence of LPE in the upper well;
(+) LPE indicates the presence of LPE in the upper well. SK-OV3 cells
preincubated in the absence or presence of 100 ng/ml of pertussis toxin
for 24 h, were subjected to chemotaxis assays at LPE concentrations of
0, 1, and 10 lM (B). Migrated cell numbers were determined by
counting in 3 high power ﬁelds (400·). Data are presented as
means ± S.E. of three independent experiments performed in
duplicate. *P < 0.05 from vehicle treated. #P < 0.05 from LPE only
treated.
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Fig. 4. LPE stimulates matrigel invasion by SK-OV3 cells. For
invasion assays, the lower and upper parts of Transwells were coated
with Matrigel. SK-OV3 cells cultured in the absence or presence of
several concentrations of LPE, or vehicle (DDW) were placed in the
upper well. Cell invasiveness was determined by determining the ability
of cells to pass through the Matrigel-coated ﬁlter. After 24 h, cells on
the bottom of the ﬁlter were ﬁxed, stained, and counted as described in
Section 2. The data shown represent the means ± S.E. of two separate
experiments performed in duplicate. *P < 0.05 from vehicle treated.
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Fig. 5. LPE-induced [Ca2+]i increase is independent of LPA receptors
4414 K.S. Park et al. / FEBS Letters 581 (2007) 4411–4416to LPA receptors, we utilized NF-jB-driven luciferase activity.
At ﬁrst we observed that treatment of LPA or LPE induced
NF-jB-driven luciferase activity in NF-jB-luciferase transfec-
ted SK-OV3 cells (data not shown). And next, we investigated
the eﬀect of LPA or LPE on NF-jB activity in LPA1, LPA2,
LPA3, LPA4, or LPA5-transfected HepG2 cells. As shown in
Fig. 6B, treatment of LPA elicited NF-jB-driven luciferase
activity in LPA1, LPA2, LPA3, LPA4, or LPA5-transfected
HepG2 cells. However, LPE failed to stimulate NF-jB-driven
luciferase activity in the cells (Fig. 6B). These ﬁndings strongly
indicate that LPE is not an agonist for the ﬁve known LPA
receptors, LPA1, LPA2, LPA3, LPA4, and LPA5.in OVCAR-3 cells. Fura-2-loaded SK-OV3 cells were challenged with
10 lM LPE or 20 lM LPA at the time indicated by the arrow (A).
Fura-2-loaded SK-OV3 cells were pretreated with vehicle (DMSO),
10 lM of VPC32183 (B) or 10 lM of Ki16425 (C) prior to 10 lM of
LPE or 20 lM of LPA. Relative intracellular Ca2+ concentrations are
expressed as ﬂuorescence ratios (340:380 nm). Data are representative
of four independent experiments (A–C).4. Discussion
Accumulating evidence that several lysophospholipids act as
cytokine-like molecules led us to examine the eﬀect of LPE on
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Fig. 6. LPE does not stimulate LPA receptors. mRNA was isolated
from SK-OV3, Ovar-3, A431, HCT116, Hela, MCF-7, and U937.
Semiquantitative RT-PCR was performed to determine LPA1, LPA2,
LPA3, LPA4, and LPA5 mRNA expressions. Control lanes were
ampliﬁed using plasmids containing each LPA receptor. The data
shown are representative of three independent experiments (A). LPA1,
LPA2, LPA3, LPA4, or LPA5 cDNA and NF-jB-luciferase construct
were co-transfected into HepG2 cells. Cells were stimulated with LPA
(10 lM) or LPE (10 lM) for 20 h (B). Luciferase activities were
measured in cell lysates using luciferase reporter gene assays. The data
represent mean ± S.E. from at least three separate experiments
performed in duplicate (B). *P < 0.05 from vehicle treated.
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that LPE speciﬁcally stimulated [Ca2+]i increase in ovarian can-
cer cells. On the functional aspect, we found that LPE stimu-
lated chemotactic migration and cellular invasion in SK-OV3
ovarian cancer cells. We also found that certain type of cell sur-
face receptors, which are coupled to PTX-sensitive G-proteins
and independent to known LPA receptors, are involved in the
activation process of ovarian cancer cells by LPE.
Previously, it has been reported that LPA is present at high
concentrations in ascites of ovarian cancer patients [20,21].
Furthermore, it has been demonstrated that LPA has very
important roles in the pathogenesis of ovarian cancer cells
[3,22]. LPA acts as a growth factor in ovarian cancer cells,
resulting in proliferation of the cells [20]. LPA also induces
the expression of various genes, including c-fos, c-myc,
Egr-1, cyclooxygenase-2, and vascular endothelial growth fac-
tor [3,23,24]. In addition, LPA increases the expression of cer-
tain types of proteases such as uPA, matrix metalloproteinases,
which are important mediators for ovarian cancer cells to
migrate and metastasize [25]. Although LPA has various roles
in the pathogenesis of ovarian cancer cells, the roles of other
lysophospholipids have not been fully considered. Here, in this
study, we for the ﬁrst time demonstrated that another
lysophospholipid, LPE, has important roles on the modulation
of ovarian cancer cell activity. LPE stimulated chemotacticmigration and cellular invasion of ovarian cancer cells (Figs.
3 and 4). Although little information is available on the
(patho)physiological concentration of LPE in ascites of ovar-
ian cancer patients and its role on the pathogenesis of ovarian
cancer cells, our study suggest signiﬁcance of LPE as a bioac-
tive mediator in ovarian cancer. Further studies are favored to
reveal the concentration of LPE in ascites and production
mechanism of LPE in ovarian carcinogenesis.
In terms of molecular target for LPE, we tested the possibil-
ity that LPE use certain types of GPCR. At ﬁrst, we observed
that LPE-induced calcium signaling was completely inhib-
ited by suramin, which has been reported to inhibit GPCR
signaling (data not shown). We, then, demonstrated that
preincubation of SK-OV3 cells with PTX completely inhibited
LPE-induced calcium signaling (Fig. 2B), suggesting the
involvement of PTX-sensitive G-protein(s). We also examined
the possibility that LPE binds to LPA receptors by monitoring
calcium signaling by consecutive treatments of lysolipids. LPE-
induced Ca2+ response was desensitized by prior treatment of
LPE, however, LPE-induced Ca2+ response was not desensi-
tized by the treatment of LPA (Fig. 5A). Furthermore,
LPE-induced calcium signaling was not inhibited by two struc-
turally diﬀerent antagonists for LPA1/3 receptors (VPC32183
and Ki16425) (Fig. 5B and C), though LPA-induced calcium
rise was almost completely inhibited by the two antagonists
(Fig. 5B and C). In order to investigate whether LPE act on
LPA receptors, we tested the eﬀect of LPE on LPA receptor-
mediated signaling. As shown in Fig. 6B, LPE failed to stimu-
late NF-jB-driven luciferase activity in HepG2 cells expressing
LPA1, LPA2, LPA3, LPA4, or LPA5 exogenously. From these
results, we suggest that LPE binds to its own receptor, which is
distinct to LPA receptors, in SK-OV3 ovarian cancer cells. We
also tested the eﬀects of two additional lysophospholipids
(LPG and sphingosine 1-phosphate) on the LPE-induced cal-
cium signaling. The two tested lysophospholipids treatments
did not elicit desensitization of calcium signaling induced by
LPE (data not shown). In terms of the role of LPS on LPE-
induced calcium increase, we observed that SK-OV3 does
not express a known LPS receptor (GPR34) (data not shown).
These results suggest that LPE stimulates calcium signaling
independent of LPS receptor (GPR34) as well as sphingosine
1-phosphate or LPG receptors.
In this study, we investigated the eﬀect of PTX, which specif-
ically inactivates Gi/Go-mediated signaling pathways, on LPE-
induced signaling and cellular responses. Preincubation of
SK-OV3 cells with 100 ng/ml of PTX for 24 h completely
inhibited LPE-induced [Ca2+]i (Fig. 2B), indicating that LPE
utilizes PTX-sensitive GPCR. LPE-induced chemotactic
migration was also completely inhibited by PTX (Fig. 4B).
Taken together, the results suggest that LPE induces PTX-
sensitive G-protein-dependent [Ca2+]i increase and chemotac-
tic migration in SK-OV3 human ovarian cancer cells. To our
knowledge, it will be the ﬁrst report that demonstrates the role
of PTX-sensitive trimeric G-proteins and GPCRs for LPE.
Because this is the only report upon the role of LPE on calcium
signaling in human ovarian cancer cells, further studies on the
pathological roles of LPE and on the identity of speciﬁc cell
surface receptor(s) for LPE in human ovarian cancer cells
are required.Acknowledgement: This work was supported by the Korea Science and
Engineering Foundation Grant (R01-2005-000-10011-02005).
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